Is Scholar Rock Holding Corp (SRRK) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.4% / 30% | 9.5% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 1.4% / 33% | 9.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 13.7% / 33% | 92.1% / 33% | 0.5% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.4% / 33% | 9.5% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 13.7% / 33% | 92.1% / 33% | 0.5% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -123.1% | |
| Return on Assets (ROA) | -54.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$300M |
| Free Cash Flow | -$301M |
| Total Debt | $109M |
| Debt-to-Equity | 44.4 |
| Current Ratio | 7.0 |
| Total Assets | $404M |
Price & Trading
| Last Close | $44.21 |
| 50-Day MA | $45.07 |
| 200-Day MA | $38.61 |
| Avg Volume | 1.1M |
| Beta | 0.7 |
|
52-Week Range
$22.71
| |
About Scholar Rock Holding Corp (SRRK)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Scholar Rock Holding Corp (SRRK) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Scholar Rock Holding Corp is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Scholar Rock Holding Corp's debt ratio?
Scholar Rock Holding Corp's debt ratio is 1.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 13.7%.
What are Scholar Rock Holding Corp's key financial metrics?
Scholar Rock Holding Corp has a market capitalization of $4.9B. Return on equity stands at -123.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.